0002117902 2026-06-10 2026-06-10 0002117902 1 2026-06-10 2026-06-10 iso4217:USD pure KUVA LABS INC. false 32175207.17 0.0001381 4443.4 32175207.17 4443.4 0 0 4443.4 <table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;"> </td><td style="width: 99%;"> </td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; vertical-align: top;"> <div style="margin-bottom: 4pt;"> * </div> </td> <td style="padding: 0px 5.4pt 0px 5px; text-align: justify; vertical-align: top;"> <div style="margin-bottom: 4pt;"> Estimated for purposes of calculating the filing fee only. The transaction valuation was estimated by adding: (i) the product of (A) the sum of (1) 9,101,943 shares of common stock, par value $0.001 per share (the “Common Shares”) of Lisata Therapeutics, Inc. (the “Company”), issued and outstanding and (2) 476,862 Common Shares subject to outstanding restricted stock units; and (B) $3.34, the average of the high and low sales prices per Common Share on June 5, 2026, as reported by the Nasdaq Capital Market (which, for the purposes of calculating the filing fee only, shall be deemed to be the “Reference Price”); (ii) the product of (A) 10,000 shares of preferred stock, par value $0.01 (the “Preferred Shares”) of the Company, issued and outstanding and (B) the merger consideration payable in respect of each Preferred Share of $0.0005 per share; (iii) the product of (A) 641,567 Common Shares subject to outstanding in-the-money stock options and (B) the Reference Price minus $3.12, the weighted average exercise price of the outstanding in-the-money stock options; and (iv) 11,996 Common Shares estimated to be subject to outstanding purchase rights under the Company’s 2017 Employee Stock Purchase Plan, multiplied by the Reference Price. All Common Share and Preferred Share amounts are based on information provided by the Company as of June 8, 2026. </div> </td> </tr> </table><table style="font-size: 10pt; border-spacing: 0px; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;"> </td><td style="width: 99%;"> </td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; vertical-align: top;"> <div style="margin-bottom: 4pt;"> <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">**</span> </div> </td> <td style="padding: 0px 5.4pt 0px 5px; text-align: justify; vertical-align: top;"> <div style="margin-bottom: 4pt;"> The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and the Section 6(b) Filing Fee Rate Advisory for Fiscal Year 2026 beginning on October 1, 2025, issued August 25, 2025, by multiplying the transaction value by 0.00013810. </div> </td> </tr> </table> SC TO 0002117902 EX-FILING FEES N/A SC TO-T